Theravance (THRX)

	SUMMARY

	BULLS

	BEARS

	TOPICS

	DATA CENTRAL

	STOCK CHART

	SEC FILINGS

	BALANCE

	INCOME

	CASH FLOW

Annual Reports

Quarterly Reports

8-K

8-K (May 13, 2013)8-K (May 10, 2013)8-K (Apr 29, 2013)8-K (Apr 25, 2013)8-K (Apr 17, 2013)8-K (Apr 15, 2013)8-K (Mar 26, 2013)8-K (Mar 20, 2013)8-K (Mar 11, 2013)8-K (Mar 6, 2013)8-K (Feb 19, 2013)8-K (Feb 12, 2013)8-K (Jan 25, 2013)8-K (Jan 23, 2013)8-K (Jan 16, 2013)8-K (Jan 9, 2013)8-K (Dec 18, 2012)8-K (Dec 14, 2012)8-K (Nov 29, 2012)8-K (Nov 27, 2012)8-K (Oct 30, 2012)8-K (Oct 24, 2012)8-K (Oct 23, 2012)8-K (Oct 16, 2012)8-K (Oct 2, 2012)8-K (Sep 26, 2012)8-K (Sep 19, 2012)8-K (Sep 4, 2012)8-K (Aug 24, 2012)8-K (Jul 31, 2012)8-K (Jul 13, 2012)8-K (Jul 10, 2012)8-K (Jul 2, 2012)8-K (Jun 19, 2012)8-K (May 24, 2012)8-K (May 22, 2012)8-K (May 17, 2012)8-K (May 16, 2012)8-K (Apr 26, 2012)8-K (Apr 2, 2012)8-K (Mar 23, 2012)8-K (Feb 16, 2012)8-K (Feb 9, 2012)8-K (Jan 9, 2012)8-K (Jan 6, 2012)8-K (Dec 2, 2011)8-K (Nov 17, 2011)8-K (Nov 14, 2011)8-K (Oct 27, 2011)8-K (Sep 26, 2011)8-K (Sep 15, 2011)8-K (Jul 28, 2011)8-K (Jun 2, 2011)8-K (May 20, 2011)8-K (May 17, 2011)8-K (May 16, 2011)8-K (May 2, 2011)8-K (Apr 28, 2011)8-K (Feb 15, 2011)8-K (Feb 3, 2011)8-K (Jan 12, 2011)8-K (Dec 21, 2010)8-K (Dec 17, 2010)8-K (Nov 29, 2010)8-K (Oct 22, 2010)8-K (Oct 21, 2010)8-K (Sep 22, 2010)8-K (Sep 20, 2010)8-K (Jul 22, 2010)8-K (Jul 6, 2010)8-K (Jun 8, 2010)8-K (May 19, 2010)8-K (May 18, 2010)8-K (Apr 30, 2010)8-K (Apr 21, 2010)8-K (Mar 24, 2010)8-K (Mar 17, 2010)8-K (Feb 11, 2010)8-K (Jan 28, 2010)8-K (Jan 20, 2010)8-K (Jan 14, 2010)8-K (Dec 15, 2009)8-K (Nov 27, 2009)8-K (Oct 27, 2009)8-K (Sep 14, 2009)8-K (Jul 23, 2009)8-K (Apr 24, 2009)8-K (Apr 22, 2009)8-K (Apr 6, 2009)8-K (Feb 26, 2009)8-K (Feb 12, 2009)8-K (Feb 4, 2009)8-K (Jan 26, 2009)8-K (Dec 22, 2008)8-K (Dec 11, 2008)8-K (Dec 2, 2008)8-K (Nov 25, 2008)8-K (Nov 19, 2008)8-K (Oct 27, 2008)8-K (Oct 23, 2008)8-K (Oct 14, 2008)8-K (Jul 24, 2008)8-K (Jul 14, 2008)8-K (Jun 19, 2008)8-K (May 20, 2008)8-K (Apr 24, 2008)8-K (Apr 21, 2008)8-K (Mar 19, 2008)8-K (Mar 5, 2008)8-K (Mar 3, 2008)8-K (Feb 14, 2008)8-K (Feb 1, 2008)8-K (Jan 23, 2008)8-K (Jan 15, 2008)8-K (Jan 11, 2008)8-K (Jan 7, 2008)8-K (Dec 5, 2007)8-K (Oct 25, 2007)8-K (Oct 22, 2007)8-K (Oct 17, 2007)8-K (Sep 13, 2007)8-K (Sep 6, 2007)8-K (Jul 31, 2007)8-K (Jul 26, 2007)8-K (Jul 20, 2007)8-K (Jul 11, 2007)8-K (Jul 9, 2007)8-K (Jul 3, 2007)8-K (Jun 29, 2007)8-K (Apr 30, 2007)8-K (Apr 26, 2007)8-K (Feb 21, 2007)8-K (Feb 20, 2007)8-K (Feb 8, 2007)8-K (Dec 8, 2006)8-K (Oct 26, 2006)8-K (Oct 10, 2006)8-K (Aug 22, 2006)8-K (Jul 27, 2006)8-K (Jul 18, 2006)8-K (May 12, 2006)8-K (May 2, 2006)8-K (Apr 27, 2006)8-K (Feb 10, 2006)8-K (Feb 9, 2006)8-K (Feb 3, 2006)8-K (Jan 30, 2006)8-K (Jan 11, 2006)8-K (Dec 12, 2005)8-K (Nov 8, 2005)8-K (Oct 27, 2005)8-K (Sep 2, 2005)8-K (Jul 27, 2005)8-K (Jul 21, 2005)8-K (May 4, 2005)8-K (Feb 16, 2005)8-K (Feb 4, 2005)8-K (Nov 3, 2004)8-K (Oct 8, 2004)

Other

Theravance 8-K 2012

Documents found in this filing:

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

Current Report Pursuant

to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): June 19, 2012

THERAVANCE, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware

(State or Other Jurisdiction of
Incorporation)

000-30319

(Commission File Number)

94-3265960

(I.R.S. Employer Identification Number)

901 Gateway Boulevard
South San Francisco, California 94080
(650) 808-6000

(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

Today at the European Academy of Allergy and Clinical Immunology Congress 2012 in Geneva, Switzerland, GlaxoSmithKline (GSK) presented a poster containing information from a Phase 2a study with RELOVAIR™. RELOVAIR™ is a once-daily inhaled corticosteroid (ICS)/long-acting beta-agonist (LABA) combination treatment, comprising fluticasone furoate and vilanterol (FF/VI), currently in development for the treatment of patients with chronic obstructive pulmonary disease (COPD) and patients with asthma, under the LABA collaboration agreement between GSK and Theravance, Inc. The poster is filed as Exhibit 99.1 to this report and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit		Description
Exhibit 99.1		Fluticasone furoate and vilanterol suppress allergen-induced bronchial hyper-responsiveness to methacholine

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	THERAVANCE, INC.

Date: June 19, 2012	By:	/s/ Michael W. Aguiar
		Michael W. Aguiar
		Chief Financial Officer

EXHIBIT INDEX

Exhibit		Description
Exhibit 99.1		Fluticasone furoate and vilanterol suppress allergen-induced bronchial hyper-responsiveness to methacholine

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.

Mobile | Advertise | Licensing & Partnerships | Blogger Tools | Jobs

Theravance (THRX)

Annual Reports

Quarterly Reports

8-K

Other

Documents found in this filing: